This Slideshare presentation is a partial preview of the full business document. To view and download the full document, please go here: http://flevy.com/browse/business-document/pharma-disease-insight-oncology-breast-cancer-2850 DOCUMENT DESCRIPTION The breast cancer therapy market was the largest in oncology across the major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) in 2015 with sales of $13.8 billion. Sales are set to soar throughout our forecast period to $30.5 billion by 2025, driven by uptake of both current and emerging agents in multiple treatment settings. Two drug classes, HER2-targeted agents and CDK4/6 inhibitors, will account for over 60% of sales in this market in 2025. Currently approved therapies will continue to have a meaningful impact on the breast cancer treatment algorithm and market sales. Pfizer's CDK4/6 inhibitor Ibrance will experience increasing use in the HR-positive, HER2-negative population, fueling this agent's sales to exceed $8.5 billion at its peak. Roche/Genentech/Chugai's HER2-targeted MAb, Perjeta, will continue to gain traction in the market, with its forecast adjuvant approval bolstering sales to exceed $5 billion in 2025. INTRODUCTION 1. Key Findings 2. Market Share of Colorectal Cancer Drug Classes in 2015 and 2025 3. Disease Market SWOT Analysis ETIOLOGY AND PATHOPHYSIOLOGY 1. Key Findings 2. Expert Insight 3. Disease Overview 4. Disease Pathophysiology 5. Etiology 6. Pathophysiology KEY PATHWAYS AND DRUG TARGETS MARKET OUTLOOK 1. Key Findings 2. Expert Insight 3. Market Overview 4. What Factors Are Driving the Market 5. What Factors Are Constraining the Market